Organotypic epithelial raft cultures as a model for evaluating compounds against alphaherpesviruses

Antimicrobial Agents and Chemotherapy

Volumn 49, Issue 11, 2005, Pages 4671-4680

  Andrei, Graciela ^a   Van Den Oord, Joost ^b   Fiten, Pierre ^a   Opdenakker, Ghislain ^a   De Wolf Peeters, Chris ^b   De Clercq, Erik ^a   Snoeck, Robert ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

5 (2 BROMOVINYL) 2' DEOXYURIDINE; ACICLOVIR; ANTIVIRUS AGENT; CIDOFOVIR; FOSCARNET; PENCICLOVIR; VIRUS DNA;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CELL CULTURE; CELL DIFFERENTIATION; CELL TRANSFORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; DRUG EFFICACY; EPITHELIUM; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HERPES VIRUS; HUMAN; HUMAN CELL; IN VIVO STUDY; KERATINOCYTE; MOUSE; MULTINUCLEAR CELL; NEWBORN; NONHUMAN; PREPUCE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SQUAMOUS EPITHELIUM; VARICELLA ZOSTER VIRUS; VIRUS STRAIN; VIRUS TITRATION; WILD TYPE;

ALPHAHERPESVIRINAE; ANIMALS; ANTIVIRAL AGENTS; CELL DIFFERENTIATION; CELLS, CULTURED; EPITHELIAL CELLS; HUMANS; KERATINOCYTES; MICE; SWISS 3T3 CELLS;

EID: 27644491910     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.49.11.4671-4680.2005     Document Type: Article

References (28)

1. Andrei, G., R. Snoeck, and E. De Clercq. 1994. Human brain tumor cell lines as cell substrates to demonstrate sensitivity/resistance of herpes simplex virus types 1 and 2 to acyclic nucleoside analogues. Antiviral Chem. Chemother. 5:263-270.
2. Andrei, G., R. Snoeck, E. De Clercq, R. Esnouf, P. Fiten, and G. Opdenakker. 2000. Resistance of herpes simplex virus type 1 against different phosphonylmethoxyalkyl derivatives of purines and pyrimidines due to specific mutations in the viral DNA polymerase gene. J. Gen. Virol. 81:639-648.
3. Andrei, G., R. Sienaert, C. McGuigan, E. De Clercq, J. Balzarini, and R. Snoeck. 2005. Susceptibilities of several clinical varicella-zoster virus (VZV) isolates and drug-resistant VZV strains to bicyclic furanopyrimidine nucleosides. Antimicrob. Agents Chemother. 49:1081-1086.
4. Arvin, A. M. 2001. Varicella-zoster virus, p. 2731-2767. In D. M. Knipe, P. M. Howley, D. E. Griffin, R. A. Lamb, M. A. Martin, B. Roizman, and S. E. Straus (ed.), Fields virology, 4th ed., vol. 2. Lippincott Williams & Wilkins, Philadelphia, Pa.
5. Besser, J., M. Ikoma, K. Fabel, M. H. Sommer, L. Zerboni, C. Grose, and A. M. Arvin. 2004. Differential requirements for cell fusion and virion formation in the pathogenesis of varicella-zoster virus infection in skin and T cells. J. Virol. 78:13293-13305.
6. Chow, L. T., and T. Broker. 1997. In vitro experimental systems for HPV: epithelial raft cultures for investigations of viral reproduction and pathogenesis and for genetic analyses of viral proteins and regulatory sequences. Clin. Dermatol. 15:217-227.
7. De Clercq, E. 1982. Comparative efficacy of antiherpes drugs in different cell lines. Antimicrob Agents Chemother. 21:661-663.
8. De Clercq, E. 2003. Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections. Clin. Microbiol. Rev. 16:569-596.
9. Gelb, L. D. 1993. Varicella-zoster virus: clinical aspects, p. 281-308. In B. Roizman, R. J. Whitley, and C. Lopez (ed.), The human herpesviruses. Raven Press, Ltd., New York, NY.
10. Hukkanen, V., H. Mikola, M. Nykänen, and S. Syrjänen. 1999. Herpes simplex virus type 1 infection has two separate modes of spread in three-dimensional keratinocyte culture. J. Gen. Virol. 80:2149-2155.
11. Jung, B. F., R. W. Johnson, D. R. Griffin, and R. H. Dworkin. 2004. Risk factors for postherpetic neuralgia in patients with herpes zoster. Neurology 62:1545-1551.
12. + T lymphocytes that express activation, memory, and skin homing markers. J. Virol. 76:11425-11433.
13. Leary, J. J., R. Wittrock, R. T. Sarisky, A. Weinberg, and M. J. Levin. 2002. Susceptibilities of herpes simplex viruses to penciclovir and acyclovir in eight cell lines. Antimicrob. Agents Chemother. 46:762-768.
14. Meyers, C., and L. A. Laimins. 1994. In vitro systems for the study and propagation of human papillomaviruses. Curr. Top. Microbiol. Immunol. 186:199-215.
15. Meyers C., M. Mane, N. Kokorina, S. Alam, and P. L. Hermonat. 2000. Ubiquitous human adeno-associated virus type 2 autonomously replicates in differentiating keratinocytes of a normal skin model. Virology 272:338-346.
16. Meyers, C., S. S. Andreansky, and R. J. Courtney. 2003. Replication and interaction of herpes simplex virus and human papillomavirus in differentiating host epithelial tissue. Virology 315:43-55.
17. + T lymphocytes and epidermal cells in SCID-hu mouse. J. Virol. 69:5236-5242.
18. Moffat, J. F., L. Zerboni, P. R. Kinchington, C. Grose, H. Kaneshima, and A. M. Arvin. 1998. Attenuation of the vaccine Oka strain of varicella-zoster virus and role of glycoprotein C in alphaherpesvirus virulence demonstrated in the SCID-hu mouse. J. Virol. 72:965-974.
19. Sexton, C. J., H. A. Navsaria, I. M. Leigh, and K. Powell. 1992. Replication of varicella-zoster virus in primary human keratinocytes. J. Med. Virol. 38:260-264.
20. Snoeck R., G. Andrei, M. Gerard, A. Silverman, A. Hedderman, J. Balzarini, C. Sadzot-Delvaux, G. Tricot, N. Clumeck, N., and E. De Clercq. 1994. Successful treatment of progressive mucocutaneous infection due to acyclovir- and foscarnet-resistant herpes simplex virus with (S)-1-(3-hydroxy-2- phosphonylmethoxypropyl)cytosine (HPMPC). Clin. Infect. Dis. 18:570-578.
21. Snoeck, R., G. Andrei, and E. De Clercq. 1999. Current pharmacological approaches to the therapy of varicella zoster virus infections: a guide to treatment. Drugs 57:187-206.
22. Snoeck, R., A. Holý, C., C. Dewolf-Peeters, J. Van den Oord, E. De Clercq, and G. Andrei. 2002. Antivaccinia activities of acyclic nucleoside phosphonate derivatives in epithelial cells and organotypic cultures. Antimicrob. Agents Chemother. 46:3356-3361.
23. Stankus, S. J., M. Dlugopolski, and D. Packer. 2000. Management of herpes zoster (shingles) and postherpetic neuralgia. Am. Fam. Physician 61:2437-2448.
24. Syrjänen, S., H. Mikola, M. Nykänen, and V. Hukkanen. 1996. In vitro establishment of lytic and nonproductive infection by herpes simplex virus type 1 in three-dimensional keratinocyte culture. J. Virol. 70:6524-6528.
25. Visalli, R. J., R. J. Courtney, M. Nykänen, and V. Hukkanen. 1997. Infection and replication of herpes simplex virus type 1 in an organotypic epithelial culture system. Virology 230:236-243.
26. Whitley, R. J., and J. W. Gnann, Jr. 1993. The epidemiology and clinical manifestations of herpes simplex virus infections, p. 69-105. In B. Roizman, R. J. Whitley, and C. Lopez (ed.), The human herpesviruses. Raven Press, Ltd., New York, NY.
27. Whitley, R. J. 2001. Herpes simplex viruses, p. 2461-2509. In D. M. Knipe, P. M. Howley, D. E. Griffin, R. A. Lamb, M. A. Martin, B. Roizman, and S. E. Straus (ed.), Fields virology, 4th ed., vol. 2. Lippincott Williams & Wilkins, Philadelphia, Pa.
28. Wutzler, P. 1997. Antiviral therapy of herpes simplex and varicella-zoster virus infections. Intervirology 40:343-356.